Prolonged Survival on PARP Inhibitor Therapy In a Patient With Stage IV Non-small Cell Lung Cancer: A Case Report
Article Information
Ana Lucia Gonzalez Herrera, Mustafa Al Gburi MD, Ahmed Ayad MD, Julio Peguero MD*
Department of Research, Oncology Consultants, Houston, Texas, USA
*Corresponding Author: Dr. Julio Peguero, Department of Research, Oncology Consultants, P.A, Houston, Texas
Received: 03 March 2019; Accepted: 13 March 2019; Published: 21 March 2019
Citation: Ana Lucía González Herrera, Mustafa Al Gburi MD, Ahmed Ayad MD, Julio Peguero MD, Karunatilleke Anne, Shah Palak, Dhamrait Bajinder. Prolonged Survival on PARP Inhibitor Therapy In a Patient With Stage IV Non-small Cell Lung Cancer: A Case Report. Archives of Clinical and Medical Case Reports 3 (2019): 59-61.
View / Download Pdf Share at FacebookAbstract
A BRCA1 mutation has been identified in a 56-year old female with adenocarcinoma of the lung. Following partial response with Nivolumab therapy, the patient started maintenance therapy with Olaparib, a PolyADP-ribose Polymerase (PARP) inhibitor showing sustained progression free response that is still ongoing.
Keywords
Non-small cell lung cancer, NSCLC, Stage IV, PARP inhibitors, Olaparib, BRCA1 duplication
Non-small cell lung cancer articles Non-small cell lung cancer Research articles Non-small cell lung cancer review articles Non-small cell lung cancer PubMed articles Non-small cell lung cancer PubMed Central articles Non-small cell lung cancer 2023 articles Non-small cell lung cancer 2024 articles Non-small cell lung cancer Scopus articles Non-small cell lung cancer impact factor journals Non-small cell lung cancer Scopus journals Non-small cell lung cancer PubMed journals Non-small cell lung cancer medical journals Non-small cell lung cancer free journals Non-small cell lung cancer best journals Non-small cell lung cancer top journals Non-small cell lung cancer free medical journals Non-small cell lung cancer famous journals Non-small cell lung cancer Google Scholar indexed journals NSCLC articles NSCLC Research articles NSCLC review articles NSCLC PubMed articles NSCLC PubMed Central articles NSCLC 2023 articles NSCLC 2024 articles NSCLC Scopus articles NSCLC impact factor journals NSCLC Scopus journals NSCLC PubMed journals NSCLC medical journals NSCLC free journals NSCLC best journals NSCLC top journals NSCLC free medical journals NSCLC famous journals NSCLC Google Scholar indexed journals Stage IV articles Stage IV Research articles Stage IV review articles Stage IV PubMed articles Stage IV PubMed Central articles Stage IV 2023 articles Stage IV 2024 articles Stage IV Scopus articles Stage IV impact factor journals Stage IV Scopus journals Stage IV PubMed journals Stage IV medical journals Stage IV free journals Stage IV best journals Stage IV top journals Stage IV free medical journals Stage IV famous journals Stage IV Google Scholar indexed journals health articles health Research articles health review articles health PubMed articles health PubMed Central articles health 2023 articles health 2024 articles health Scopus articles health impact factor journals health Scopus journals health PubMed journals health medical journals health free journals health best journals health top journals health free medical journals health famous journals health Google Scholar indexed journals PARP inhibitors articles PARP inhibitors Research articles PARP inhibitors review articles PARP inhibitors PubMed articles PARP inhibitors PubMed Central articles PARP inhibitors 2023 articles PARP inhibitors 2024 articles PARP inhibitors Scopus articles PARP inhibitors impact factor journals PARP inhibitors Scopus journals PARP inhibitors PubMed journals PARP inhibitors medical journals PARP inhibitors free journals PARP inhibitors best journals PARP inhibitors top journals PARP inhibitors free medical journals PARP inhibitors famous journals PARP inhibitors Google Scholar indexed journals Olaparib articles Olaparib Research articles Olaparib review articles Olaparib PubMed articles Olaparib PubMed Central articles Olaparib 2023 articles Olaparib 2024 articles Olaparib Scopus articles Olaparib impact factor journals Olaparib Scopus journals Olaparib PubMed journals Olaparib medical journals Olaparib free journals Olaparib best journals Olaparib top journals Olaparib free medical journals Olaparib famous journals Olaparib Google Scholar indexed journals BRCA1 duplication articles BRCA1 duplication Research articles BRCA1 duplication review articles BRCA1 duplication PubMed articles BRCA1 duplication PubMed Central articles BRCA1 duplication 2023 articles BRCA1 duplication 2024 articles BRCA1 duplication Scopus articles BRCA1 duplication impact factor journals BRCA1 duplication Scopus journals BRCA1 duplication PubMed journals BRCA1 duplication medical journals BRCA1 duplication free journals BRCA1 duplication best journals BRCA1 duplication top journals BRCA1 duplication free medical journals BRCA1 duplication famous journals BRCA1 duplication Google Scholar indexed journals patient articles patient Research articles patient review articles patient PubMed articles patient PubMed Central articles patient 2023 articles patient 2024 articles patient Scopus articles patient impact factor journals patient Scopus journals patient PubMed journals patient medical journals patient free journals patient best journals patient top journals patient free medical journals patient famous journals patient Google Scholar indexed journals medicine articles medicine Research articles medicine review articles medicine PubMed articles medicine PubMed Central articles medicine 2023 articles medicine 2024 articles medicine Scopus articles medicine impact factor journals medicine Scopus journals medicine PubMed journals medicine medical journals medicine free journals medicine best journals medicine top journals medicine free medical journals medicine famous journals medicine Google Scholar indexed journals PolyADP-ribose Polymerase articles PolyADP-ribose Polymerase Research articles PolyADP-ribose Polymerase review articles PolyADP-ribose Polymerase PubMed articles PolyADP-ribose Polymerase PubMed Central articles PolyADP-ribose Polymerase 2023 articles PolyADP-ribose Polymerase 2024 articles PolyADP-ribose Polymerase Scopus articles PolyADP-ribose Polymerase impact factor journals PolyADP-ribose Polymerase Scopus journals PolyADP-ribose Polymerase PubMed journals PolyADP-ribose Polymerase medical journals PolyADP-ribose Polymerase free journals PolyADP-ribose Polymerase best journals PolyADP-ribose Polymerase top journals PolyADP-ribose Polymerase free medical journals PolyADP-ribose Polymerase famous journals PolyADP-ribose Polymerase Google Scholar indexed journals
Article Details
1. Case Presentation
A 56-year-old Caucasian woman with a long history of tobacco smoking and alcohol consumption presented on March 2015 to our clinic with left cervical lymphadenopathy, right gluteal skin erythema and generalized weakness. Patient underwent FNA biopsy of the cervical lymph nodes and core biopsy of the gluteal soft tissue, which showed metastatic adenocarcinoma of lung origin. A CT scan of the head, neck, chest, abdomen and pelvis demonstrated a 4.2 × 3.5 cm mass in the posterior ramus of the left mandible, a subsolid nodule in the upper lobe of the left lung measuring 1.8 × 1.2 cm, multiple immeasurable nodules involving all lobes of both lungs and a rim enhancing mass adjacent to the right gluteal cleft measuring 7.3 × 5.4 cm. Further testing revealed no ALK or EGFR/CEP7 gene mutations using FISH. The patient received Carboplatin/Paclitaxel chemotherapy from November 2015 to February 2016 until disease progression was noted on routine CT scans for tumor response assessment. Chemotherapy was discontinued and treatment with Nivolumab started on March 18th, 2016, CT scans obtained one year later showed a partial response of both pulmonary and gluteal disease. Next Generation Sequencing of the tumor tissue from March 2016 showed BRCA1 duplication of exons 7-12.
After discussing treatment options for maintenance therapy with the patient, she agreed to start on Olaparib in March 2017. The latest PET-CT, obtained in October 2018 showed no hypermetabolic cervical lymphadenopathy, stable pulmonary nodules and residual skin thickening of the right gluteal mass. The patient is clinically stable at this point and taking Olaparib daily.
2. Discussion
BRCA1 mutation has been highly associated with hereditary breast and ovarian cancer, as well as other types, including prostate, gastric, colorectal and pancreatic but rarely has been reported in lung cancers, approximately only in 3.5% of sequenced tumors according to the lung adenocarcinoma TCGA dataset [1]. Over the years, the genotype of Non-small cell lung cancer has been identified and used as target therapy trying to improve prognosis.
This mutation identified in this patient makes her a candidate for targeted molecular therapies towards BRCA1/2 mutation, such as PARP inhibitors, which have been scarcely studied in this type of cancer. This makes this case unique and relevant towards demonstrating the efficacy of this class of medications in different cancer types and stages, as seen here, where the progression free survival has been largely prolonged. There are currently two-phase II trials evaluating Olaparib as a maintenance treatment in NSCLC, the PIPSeN trial and the PIN trial, which results are still pending and may show improved survival as we have seen with this patient [2, 3].
3. Conclusion
This is a case of prolonged survival in Non-small cell lung cancer observed upon BRCA gene manipulation. Few similar clinical reports are available in the medical literature. However, this case yields a selective oncogenomic pragmatic target for practicing oncologists in this field.
Acknowledgment
None.
Conflict of Interest
None.
References
- National Center Institute. GDC data portal (2019).
- National Institute of Health. Clinical Trials.gov: Trial evaluating maintenance olaparib in patients with platinum-sensitive advanced Non-small cell lung cancer (PIPSeN) (2017).
- National Institute of Health. Clinical Trials.gov: Parp inhibitor in advanced Non-small cell lung cancer (PIN) (2018).